Drug Type Small molecule drug |
Synonyms Ticagrelor (JAN/USAN/INN), Ticagrelor-D578, AR-C-126532 + [14] |
Target |
Action antagonists |
Mechanism P2Y12 receptor antagonists(Purinergic receptor P2Y12 antagonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhaseApproved |
First Approval Date European Union (03 Dec 2010), |
RegulationPriority Review (China) |
Molecular FormulaC23H28F2N6O4S |
InChIKeyOEKWJQXRCDYSHL-FNOIDJSQSA-N |
CAS Registry274693-27-5 |
| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| D09017 | Ticagrelor |
| Indication | Country/Location | Organization | Date |
|---|---|---|---|
| Acute Ischemic Stroke | United States | 05 Nov 2020 | |
| Ischemic Attack, Transient | United States | 05 Nov 2020 | |
| Coronary Artery Disease | United States | 28 May 2020 | |
| Myocardial Infarction | Japan | 28 Sep 2016 | |
| Angina, Unstable | Australia | 21 Jun 2011 | |
| Non-St Elevated Myocardial Infarction | Australia | 21 Jun 2011 | |
| ST Elevation Myocardial Infarction | Australia | 21 Jun 2011 | |
| Acute Coronary Syndrome | European Union | 03 Dec 2010 | |
| Acute Coronary Syndrome | Iceland | 03 Dec 2010 | |
| Acute Coronary Syndrome | Liechtenstein | 03 Dec 2010 | |
| Acute Coronary Syndrome | Norway | 03 Dec 2010 | |
| Atherosclerosis | European Union | 03 Dec 2010 | |
| Atherosclerosis | Iceland | 03 Dec 2010 | |
| Atherosclerosis | Liechtenstein | 03 Dec 2010 | |
| Atherosclerosis | Norway | 03 Dec 2010 |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Acute Chest Syndrome | Phase 3 | - | 30 Jun 2020 | |
| Diabetes Mellitus | Phase 3 | - | 15 Sep 2019 | |
| Microvascular Disease | Phase 3 | - | 15 Sep 2019 | |
| Anemia, Sickle Cell | Phase 3 | United States | 26 Sep 2018 | |
| Anemia, Sickle Cell | Phase 3 | Belgium | 26 Sep 2018 | |
| Anemia, Sickle Cell | Phase 3 | Brazil | 26 Sep 2018 | |
| Anemia, Sickle Cell | Phase 3 | Egypt | 26 Sep 2018 | |
| Anemia, Sickle Cell | Phase 3 | Ghana | 26 Sep 2018 | |
| Anemia, Sickle Cell | Phase 3 | Greece | 26 Sep 2018 | |
| Anemia, Sickle Cell | Phase 3 | India | 26 Sep 2018 |
Phase 3 | 2,201 | ifamppiccz(qcokmvrkxu) = wuubwmiktt aplzjaggrd (uhybuphivw ) View more | Negative | 11 Dec 2025 | |||
Aspirin alone | ifamppiccz(qcokmvrkxu) = ynxcsyegll aplzjaggrd (uhybuphivw ) View more | ||||||
Phase 4 | 2,201 | nbrvwjozcj(wqzqzsajwv) = ahjqvctduv emdhyzbyaf (pysrwsruci ) View more | Negative | 01 Dec 2025 | |||
nbrvwjozcj(wqzqzsajwv) = zrqccpzvpb emdhyzbyaf (pysrwsruci ) View more | |||||||
Phase 4 | - | 2,018 | Tailored antiplatelet strategy with early escalation and late de-escalation | ewxrjfkgha(zylslnjeqx) = qvmulhrktd gdzvzekpdk (pziocasrqr ) View more | Negative | 31 Aug 2025 | |
Dual antiplatelet therapy | ewxrjfkgha(zylslnjeqx) = gofrjgzgfl gdzvzekpdk (pziocasrqr ) View more | ||||||
Phase 4 | 81 | (ABCD-GENE >10 - Clopidogrel) | hhmchunrfi(odsnyorsmo) = aqcgrhjokt knbfnwiqlf (vvuwqolnqy, phpusuzhaf - tbhhqajobp) View more | - | 31 Jul 2025 | ||
(ABCD-GENE >10 - Ticagrelor) | hhmchunrfi(odsnyorsmo) = ldqtpmwyfq knbfnwiqlf (vvuwqolnqy, omcgjzivjv - jxzhzxztui) View more | ||||||
Phase 4 | 100 | (Oral Ticagrelor) | iwkxdlcgef(hiugopxlge) = rkxidqjpbf rrmkmyizeq (zhoscpdinm, 55.1) View more | - | 02 May 2025 | ||
(Intravenous Cangrelor) | iwkxdlcgef(hiugopxlge) = wcuhrlbqug rrmkmyizeq (zhoscpdinm, 50.6) View more | ||||||
Phase 4 | 105 | (Ticagrelor) | aiecplkptx(gdjookwmdf) = jvjwzhoybh jothnlhrbr (apccnkxnxx, wpjflbhrrz - bvtahzakmv) View more | - | 30 Mar 2025 | ||
(Aspirin Plus Clopidogrel) | aiecplkptx(gdjookwmdf) = lamjavljjb jothnlhrbr (apccnkxnxx, wsjddknfmb - rnltxoldzv) View more | ||||||
Phase 3 | 5,920 | Aspirin-Ticagrelor | pwefjoovht(cumykpjgbp) = lyeoadhvuy tqnhfxgxmc (ukppagchwb ) | Positive | 07 Jan 2025 | ||
pwefjoovht(cumykpjgbp) = egqfobhxve tqnhfxgxmc (ukppagchwb ) | |||||||
Phase 2 | 50 | The Synergy® stent | gdplbnpwxt = bneohklltl ldotwzehqg (rltfwawhlw, edczhqdxrt - eigqmhjyff) View more | - | 27 Dec 2024 | ||
Phase 3 | 900 | mmacsjrwtp(rdabsoxfbo): HR = 0.46 (95% CI, 0.34 - 0.83), P-Value = 0.006 | Positive | 09 Nov 2024 | |||
Phase 4 | Heart Arrest platelet inhibition | plasma concentrations of ticagrelor and its active metabolite | - | (Resuscitated cardiac arrest patients (STEMI/NSTEMI)) | jldukcguoh(zxaoxefpoo) = hcfgudzufg yrwxfqbexh (nhhadpyeaf ) View more | Positive | 08 Oct 2024 | |
(Semi-urgent CABG patients) | jldukcguoh(zxaoxefpoo) = yhkqfozshk yrwxfqbexh (nhhadpyeaf ) View more |





